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ABSTRACT

Angiostatin is a proteolytic fragment of plasminogen that inhibits angiogenesis. It
destroys newly formed capillaries and causes tumors to stop growing, shrink, or
disappear altogether. We sought to determine if angiostatin could be produced from
plasminogen by urokinase enzyme. We hypothesized that if angiostatin is produced, it
could be an inhibitor of endothelial cell growth. To test this idea, plasminogen was
purified by affinity chromatography using a sepharose-lysine column. Then , it was
incubated with urokinase and 10% sodium azide. In order to produce angiostatin,
samples were taken out at different time periods and analyzed on SDS-Page Gel
electrophoresis gel designated to detect angiostatin. A Western Blot analysis prove that
angiostatin was indeed present after plasminogen. We then examined angiostatin activity
to determine if angiostatin inhibits endothelial cell growth. We demonstrated that
angiostatin does indeed inhibit endothelial cell growth at the concentration produced
[rom plasminogen. Thus our results showed that plasminogen can be converted to
angiostatin by urokinase and angiostatin has shown inhibitory activity on endothelial cell
proliferation.
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CHAPTER I
BACKGROUND OF THE STUDY

INTRODUCTION

Angiogenesis is growth of new capillaries and blood vessels. This process can
cause a malignant tumor to grow and metastasize. Angiostatin is a protein that has been
shown to be an inhibitor of angiogenesis and metastatic growth. It basically starves the
cancer cells by cutting off its blood supply. Angiostatin is important because in the
future it can actually be the sole cure for the dreaded disease cancer. One problem is that
the mechanism to produce angiostatin in vivo has not been defined. However, it can be
produced in vitro (l). Angiostatin can be

~

produced by the activation of plasminogen
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by urokinase (7).
Limited proteolysis plays a pivotal
role in many regulatory reactions in the
biological systems. The activation of
plasminogen by plasminogen activators
such as urokinase has been studied in the
past. However, plasmin can be further
hydrolyzed by urokinase to form the
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(7). In our experiment, we are trying to determine if angiostatin is solely responsible for
inhibiting endothelial cell growth.

STATEMENT OF THE PROBLEM
The purpose of this research is to determine if urokinase is responsible for
inhibiting endothelial cell growth.

CHAPTER II
REVIEW OF LITERATURE

Enzymatic activity that can generate bioactive angiostatin from purified human
plasminogen or plasmin
Affinity purified PC-3 derived angiostatin inhibited endothelial cell proliferation,
basic fibroblast growth factor- induced migration, endothelial cell tube proliferation,
and basic fibroblast growth factor-induced corneal angiogenesis. Studies with proteinase
inhibitors demonstrated that a serine proteinase is necessary for angiostatin generation.
These data indicate that bioactive angiostatin can be generated directly by human prostate
cancer cells and that serine proteinase activity are necessary for angiostatin generation
(1).
Cancer-mediated proteolysis of plasminogen
Human prostate carcinoma cells (PC-3) release enzymatic activity that converts
plasminogen to angiostatin. They have now identified two components released by PC-3
cells, urokinase and free sulfhydryl donors, which are sufficient for angiostatin
generation. Cell-free derived angiostatin inhibited angiogenesis in vitro and in vivo and
suppressed the growth of Lewis lung carcinoma metastases. Theses findings define a
direct mechanism for cancer-cell mediated angiostatin generation and permit large-scale
production of bioactive angiostatin for investigation and potential therapeutic
application (2).
Biochemical Characterization of Urokinase
Angiostatin, a proteolytic fragment of plasminogen, is a potent inhibitor of
angiogenesis. In vitro, angiostatin can be generated by pancreatic elatase proteolysis of

plasminogen; however, in vivo, the enzymes responsible for angiostatin production are
not known. A recent study demonstrates the involvement of a serine protease in
angiostatin generation. In this study, they sought to determine if the human pancreatic
carcinoma cell line ASPC 1 produced enzymatic activity capable of converting
plasminogen to angiostatin and to determine if urokinase plasminogen activator is
involved in this system (3).
Application of Angiostatin
It states now there is considerable direct evidence that tumor grow is

angiogenesis-dependent. They showed that systemic administration of human angiostatin
potently inhibits the growth of three human and three murine primary carcinomas in
mice. An almost complete inhibition of tumor growth was observed without detectable
toxicity or resistance. The human carcinomas regressed to microscopic dormant foci in
which tumor cell proliferation was balanced by apoptis in the presence of blocked
angiogenesis. This is also the first demonstration of dormancy therapy, a novel
anticancer strategy in which malignant tumors are regressed by prolonged blockade of
angiogenesis (4).
Mediation of Tumor Growth
It states the phenomenon of inhibition of tumor growth by tumor mass has been

reportedly studied , but without elucidation of a satisfactory mechanism. In their animal
model , a primary tumor inhibits its remote metastases. After tumor removal, metastases
neovascularize and grow. When the primary tumor is present, metastatic growth is
suppressed by a circulating angiogenesis inhibitor. Serum and urine from tumor bearing

mice, but not from controls, specifically inhibit endothelial cell proliferation. They now
show that the inhibition of metastases by a primary mouse tumor is mediated by
angiostatin (5).
Purification and Characterization of Urokinase.
A plasminogen activator secreted by cultured human pancreatic carcinoma cells
has been purified to apparent homogeneity by procedures including Sepharose-L-arginine
methyl ester affinity chromatography and SDS gel electrophoresis. The plasminogen
activator shares many properties with urokinase including: molecular weight, isoelectric
point, heat stability, pH stability and its mode of activation of plasminogen. The
intracellul.ar enzyme is membrane bound and can be solubilized by detergent.
Solubilized activator has a molecular weight similar to that of the secreted enzyme as
determined by SDS gel electrophoresis. The production of plasminogen activator by Mia
PaCa-2 cells is totally inhibited by actinomycin D and cycloheximide (7).
Application of Urokinase
Plasminogen activator from a human pancreatic carcinoma cell line and human
urinary urokinase have been purified to homogeneity. Amino acid analysis indicated

they have a similar amino acid composition. Antibodies against both plasminogen
activators and urokinase were prepared in rabbits. Immunodiffusion experiments
revealed that both enzymes were immunologically identical. Antibodies against
plasminogen activators and urokinase cross inhibited plasminogen activators from several
other human cancer cell lines, but do not inhibit plasminogen activators from cultured rat
breast carcinoma R2426 cells (6).

CHAPTERm
METHOD SECTION

Materials and Methods
Preparation and Purification of Plasminogen
Plasminogen is prepared and purified using a sepharose-lysine affinity column.
To prepare the column, activate a sepbarose column with cyanogen bromide. Then
wash the column with 0.001 N HeL. Follow that washing with another wash with 0.1 M
sodium bicarbonate. Then incubate with L-Lysine in 0.1 M sodium bicarbonate
overnight. On the next day, block the column with glycine and re-wash the column with
0.1 M potassium phosphate buffer. Repeat tills procedure for efficiency. Now one has a
sepharose-lysine column. While repeating tills procedure thaw some plasma rapidly

in a boiling water bath. Next, centrifuge the plasma at high speed (10,000 rpm or higher)
to remove any insoluble particles. Take the centrifuged plasma and make a 1: I dilution
with potassium phosphate buffer. Load the solution into the sepharose-Iysine affmity
column. Wash again with potassium phosphate buffer (l).

Elution Profile of Plasminogen
To determine whether purified plasminogen has been produced, an elution profile
must be performed. To do so, elute the affinity column with 0.2 M e-aminocaproic acid
and collect ten 3-ml fraction of tills elution. Number each fraction as you collect it from
the affinity column. Using a spectrophotometer at OD/280nm (which is the best
absorbance reading for proteins), take the readings of the ten 3-ml fractions and create an
elution profile showing the absorbance of each fraction .

7

SDS-PAGE Gel Electrophoresis
To determine the purification of plasminogen, samples were electrophoresed
under nonreducing conditions on 12% polyacrylamide gels in tris-glycine running
buffer (4). After an hour, the gel is removed from the apparatus and placed in staining
solution overnight. The next day, remove the staining solution and add water to the gel.
Then place the gel on an ultraviolet light and record the results.

Conversion of Plasminogen to Angiostatin
Plasminogen (l mg/ml) in 0.1 M phosphate buffer, pH 7.0 was incubated with
urokinase (IOug/ml) at 37°C under sterile conditions. Samples were taken at
different time periods (0 hour, 2 hours , 5 hours, 8 hours, 31 hours) and examined by
SDS-PAOE for the reduction of plasminogen band and the appearance of two protein
bands with the molecular weight of 48 and 52 kda respectively (7). At the time of
maximum conversion, the stained protein bands will undergo Western Blot testing.

Western Blot
A Western Blot determines if any proteins are present. The stained protein bands
were electrotransferred to a 0.45 urn polyvinylene difluoride membrane. The membrane
was then blocked for 30 minutes in blocking buffer (I % BSA in tris-buffered saline) and
probed with a 1:1000 dilution of a monoclonal antibody to the kringle 1-3 fragment of
human plasminogen. After being washed , the membrane was incubated for 30 minutes
with an alkaline phosphatase conjugated goat antimouse IgO secondary antibody and
developed using 5-bromo-4-chloro-3-indoyl phosphate/nitroblue tetrazolium (2) .

8

Endothelial Cell Proliferation
Cell proliferation was determined using the Cell Titer 96 AQ nonradioactive cell
proliferation assay. The human endothelial cell, were plated in a 96-well tissue culture
plates at a concentration of 1x 1O/\4/well in 96 well plate, The cells were incubated at
37°C for 24 hours in a C02 incubator. The next day, the old growth medium was
removed from the cell culture and volumes of20ul and 100 ul of angiostatin was added to
the triplicate cells. Fresh EGM-2 medium was added to make up a volume of 300 uL and
was subsequently incubated for 72 hours, The next day the medium was removed and 10
ul ofWST-1 and 90 ul EGM-2 was added to the triplicate cells. Then an absorbance was

read at 0D495 nm reflecting the number of proliferating cells was measured using an
automated micro plate reader. The results are reported as a percentage of untreated
control cells (2).
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Figure 2 - Picture of Endothelial Cells
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CHAPTER IV

RESULTS
Preparation and Purification of Plasminogen
Purified plasminogen was produced using the Lysine-Sepharose Affinity
Chromatography. Without plasminogen, we could not have produced angiostatin. The
plasminogen produced was the basis for the entire experience.
Elution Profile of Plasminogen
This profile showed that the middle fraction has the highest absorbance, which led
us to conclude that plasminogen was indeed present.
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Table 1- Elution of Plasminogen
SDS-Gel Electrophoresis
This showed the purification of plasminogen. It shows numerous plasminogen
bands present (Lanes 2, 3, and 8). However, a stronger more distinct band appeared
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(Lane 8). That band was definitely a plasminogen band. We decided to use the
plasminogen that produced that band for the rest of the experiment.

1
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7
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Figure 3 - Purification of Plasminogen

Conversion of Plasminogen to Angiostatin
This experiment produced angiostatin. Five different samples were incubated but
were taken out at different time designations. Then a SOS Gel Electrophoresis was ran to
prove that there was a conversion of plasminogen to angiostatin. The results proved that
a smaller protein called plasmin (Lanes 4, 5, 6, 7) was produced and an even smaller
subunit in the middle portion ofthe gel (Lanes 4,5,6). We concluded that this subunit
could possibly be angiostatin. Further test had to performed to prove this hypothesis.
1

2

3

4

-

5

6

7

\

Figure 4 - Conversion of Plasminogen to Angio statin

CHAPTER V
DISCUSSION AND CONCLUSION

Angiogenesis occurs in the healthy body for healing wounds and for restoring
blood flow to tissues after injury or insult. The healthy body controls angiogenesis
through a series of growth factors and inhibitors. When angiogenic growth factors are
produced in excess of angiogenesis inhibitors, the balance is tipped in favor of blood
vessel growth. When inhibitors are present in excess of stimulators, angiogenesis is
stopped . The normal, healthy body maintains a perfect balance of angiogenesis
modulators (3). In general, angiogenesis is "turned off' by the production of more
inhibitors than stimulators.

In many serious diseases states, the body loses control over angiogenesis.
Angiogenesis-dependent diseases result when new blood vessels either grow excessively
or insufficiently. Cancer is a major disease that takes the lives of human beings every
day. Cancer causes normal cells to turn into malignant cells . These cells then trigger
another mutation that releases a chemical that tells nearby blood vessels to grow new
capillaries.
The inhibition of angiogenesis by angiostatin is directly related to inhibiting the
proliferation of endothelial cells. Angiostatin cannot be produced unless it is converted
from its precursor, plasminogen. In my experiment, I used the enzyme urokinase, which
is plasminogen activator. Urokinase digested the protein from plasminogen to plasmin
and finally to angiostatin. My experiments later proved that angiostatin inhibited

13

endothelial cell growth. However , without urokinase converting plasminogen to
angiostatin, the protein itself could not inhibit endothelial cell growth. Therefore,
urokinase is responsible for endothelial cell growth.
A substance like angiostatin (which is not just found in mice but also in humans)
could turn out to be valuable as medicine. By stopping blood vessel growth , it could stop
tumor growth and also the spread of the tumor. Once scientists begin to understand how
the mechanism is produced in vivo, angiostatin could be produced in major amounts and
people with cancer would finally have a possible long-term cure for the dreaded disease.
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